TRST.TO - CannTrust Holdings Inc.

Toronto - Toronto Delayed Price. Currency in CAD
1.2000
+0.0700 (+6.19%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1300
Open1.1900
Bid1.1900 x 0
Ask1.2000 x 0
Day's Range1.1500 - 1.2900
52 Week Range1.0400 - 13.4800
Volume1,126,595
Avg. Volume1,220,165
Market Cap179.916M
Beta (3Y Monthly)4.42
PE Ratio (TTM)N/A
EPS (TTM)-0.1210
Earnings DateMay 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.09
  • Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?
    Investor's Business Daily

    Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?

    Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.

  • CBD beverage founder: 'I want to be regulated'
    Yahoo Finance

    CBD beverage founder: 'I want to be regulated'

    Not nearly enough legislative ink has been spilled over the booming CBD industry, according to Benjamin Witte. 

  • InvestorPlace

    10 Medical Marijuana Stocks to Cure Your Portfolio

    [Editor's note: "10 Medical Marijuana Stocks to Cure Your Portfolio" was previously published in October 2019. It has since been updated to include the most relevant information available.] Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from its botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away.However, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives? * 7 Retail Stocks to Avoid for the Holidays More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell.As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: AbbVie (ABBV)Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline.We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Source: Shutterstock Not that I would know, but growing cannabis allegedly isn't rocket science.With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * 7 Retail Stocks to Avoid for the Holidays It's important to be careful with pot stocks, though. On a year-to-date basis, EMHTF stock is down 75%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)Source: Shutterstock I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is its management team. In my view, they're making smart decisions through their acquisitive strategy.Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. In the beginning of the year, shares skyrocketed roughly 70% before plummeting. It's down 28% this year. The inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)Source: Shutterstock One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Prior to its earnings report for the second quarter, I worried about the company's revenue target.Hit or exceed it, and management can stave off criticism, but speculators looking for a discounted price may want to put CRON stock back on their radar. After concerns about vaping safety hit the news, Cronos has shed all of this year's gains and more, as it's down nearly 24% YTD. * 7 Retail Stocks to Avoid for the Holidays Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)In business, even the green kind, you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry.Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical cannabis products in that country.It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand.Despite momentum toward legalization, several financial institutions shy away from cannabis ventures.Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 7 Retail Stocks to Avoid for the Holidays Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up more than 75% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category.So far this year, TRTC stock is down around 53%.And the bad news doesn't end there. Terra Tech only had $1.9 million of cash at the end of Q2.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)Source: Shutterstock When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock jumped 78% at the beginning of this year.From the opening price this year, however, Charlotte's Web shares are down over 10%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a further pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity.Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 7 Retail Stocks to Avoid for the Holidays Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana.Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network.However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure of CBIS stock. However, shares trade for $0.0049 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPH)Source: Shutterstock On a surface level, GW Pharmaceuticals (NASDAQ:GWPH) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility.Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases. * 7 Retail Stocks to Avoid for the Holidays As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Sell Before They Roll Over * 5 Beaten-Up Stocks to Buy That Could Be Saved By An Acquisition * 4 Startup Stocks Getting Smashed The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • PR Newswire

    CannTrust Provides Default Status Report

    VAUGHAN, ON, Nov. 7, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order ("MCTO") issued by the Ontario Securities Commission. The MCTO prohibits the directors and executive officers of the Company from trading in or acquiring securities of the Company until two full business days after the Company files an interim financial report for the three and six month periods ended June 30, 2019, an interim management's discussion and analysis for the corresponding period and certifications of interim filings.

  • Benzinga

    Kaden Resigns From CannTrust Board; Search Underway For New Directors, Permanent CEO

    CannTrust Holdings Inc. (TSX:TRST) (NYSE: CTST) announced Monday that John Kaden is resigning from its board of directors. The company is renewing its board following a Special Committee independent investigation and the submission of a remediation plan to Health Canada. Health Canada found the company to be in noncompliance earlier this year and later suspended its cannabis license.

  • Benzinga

    Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...

  • PR Newswire

    John Kaden Resigns from CannTrust's Board of Directors

    VAUGHAN, ON, Oct. 28, 2019 /PRNewswire/ – CannTrust Holdings Inc. ("CannTrust" or "the Company", TSX: TRST, NYSE: CTST) announced that, following both the recent submission of its detailed remediation plan to Health Canada and the completion of its Special Committee's independent investigation, the Company has begun the orderly process of renewing its Board of Directors. As part of this process, John T. Kaden has resigned from his position as Director.

  • Market Exclusive

    Cannabis Stock News Weekend Roundup October 27

    Flower One Holdings (CSE: FONE) (OTCQX: FLOOF) has announced that its brand partner has become the top-performing cannabis flower brand in Nevada. According to Headset, a cannabis industry analytics services provider, Old Pal is now the top-performing cannabis flower brand in Nevada. Flower One is licensed to produce and distribute the entire Old Pal product line. MYM […]The post Cannabis Stock News Weekend Roundup October 27 appeared first on Market Exclusive.

  • Hexo stock slides another 6% to weigh on cannabis sector after job cuts prompt downgrade
    MarketWatch

    Hexo stock slides another 6% to weigh on cannabis sector after job cuts prompt downgrade

    Hexo Corp. stock fell another 4% Friday, bringing its weekly losses to 12%, after CIBC downgraded the stock and said the 200 job cuts announced Thursday were the latest sign of the challenges facing the Quebec-based cannabis company.

  • Cannabis Update: HEXO, CTST, APHA, and ACB
    Market Realist

    Cannabis Update: HEXO, CTST, APHA, and ACB

    At 12:51 PM ET, the S&P; 500 Index and the Dow Jones Industrial Average were up 0.5% and 0.7%, respectively. The cannabis sector was also up today.

  • Reuters

    Canada's CannTrust Holdings to temporarily cut back workforce

    The company expects the cut to save about C$400,000 ($306,091.22) each month, but faces severance costs of up to C$800,000 if the employees are not recalled within 35 weeks, it said in a statement. The findings of an independent investigation panel were provided to Health Canada and the company's board, it said in the statement. The company said it gave a detailed remediation plan to Health Canada on Monday, to restore compliance.

  • MarketWatch

    CannTrust to lay off 140 workers, internal investigation into illegal pot grows complete

    CannTrust Holdings Inc. said late Thursday that it planned to lay off 140 people by the end of the year, beginning in late October. U.S.-traded shares of CannTrust stock were flat after hours. The company also said that the special committee charged with looking into the company's illegal cannabis production in Ontario, among other things, has concluded and the committee has presented the findings to the board. In addition, CannTrust said it has submitted the results to Health Canada. The Vaughn, Ontario-based weed company said it expected to release a series of restated financial statements within 60 days, but warned that "intervening events" may affect the timing.

  • PR Newswire

    CannTrust Provides Progress Update Regarding Remediation Plan

    The submission of CannTrust's detailed remediation plan to Health Canada. The Company anticipates completing all of the activities described within the plan by the end of the first quarter of 2020. The conclusion of the Special Committee's independent investigation, the findings of which have been accepted by the Company's Board of Directors.

  • MarketWatch

    UPDATE: Cronos shares surge roughly 33% in after hours

    Shares of Cronos Group Inc. rampaged in the extended session Wednesday, gaining as much as 41.5% as of 6:22 p.m. Eastern time on heavy volume, before dropping to a 33% gain at 6:45 p.m. Eastern time. It was not immediately clear why the stock surged in the extended session but two block trades totaling roughly 1.2 million shares crossed at 5:09 p.m. Eastern time at a price of $8.40 a share. If Cronos shares hold on to the gains, the late Wednesday move will be the second largest in the company's history and the largest since the company began trading on the Nasdaq. Previously other cannabis companies' stocks, such as CannTrust Holdings Inc. have notched double-digit gains because an exchange traded fund has re-balanced its portfolio after significant changes to the market price. Cronos Group stock closed up roughly 1% to $8.40 during the regular session. The stock was up 14% in premarket trade Thursday.

  • Benzinga

    One Year Later: How Every Major Cannabis Stock Has Performed Since Canadian Legalization

    Oct. 17 marks one full year of legalized cannabis in Canada — and the road to this moment could have been smoother. “Canada’s rollout of legalization has been hampered by a number of things,” Alan Brochstein, author of 420 Investor, said this week on Benzinga’s PreMarket Prep show. “They should have opened up medical dispensaries first and gotten that distribution out there,” Brochstein said.

  • CannTrust Is Up after Falling below $1
    Market Realist

    CannTrust Is Up after Falling below $1

    Today CannTrust Holdings is trading at $1.30 on the NYSE, 25.60% higher than its last closing price. It's risen even faster on the Toronto Stock Exchange.

  • Cannabis Stocks in the Green: APHA, WEED, CTST, ACB
    Market Realist

    Cannabis Stocks in the Green: APHA, WEED, CTST, ACB

    With a boost from Aphria’s (APHA) impressive first-quarter earnings, cannabis stocks and ETFs were trading higher today. Let's take a closer look.

  • TheStreet.com

    Market Wrap: C$75 Million in Pot Destroyed by CannTrust, Uber Layoffs

    Uber announced that it is laying off 350 workers just four weeks after announcing the layoffs of 435 employees.

  • Cannabis Roundup: HEXO, WEED, ACB, and CTST
    Market Realist

    Cannabis Roundup: HEXO, WEED, ACB, and CTST

    The broader US markets were relatively flat today. Weakness in the cannabis sector continued, with the ETFMG Alternative Harvest ETF down 0.4%.

  • Benzinga

    CannTrust Board Takes Next Steps To Gain Regulatory Approval

    CannTrust Holdings Inc (NYSE: CTST) shares rocketed higher by 16% on Monday after the company reported its next step in bringing its cannabis production business back into compliance following a September license suspension. CannTrust had its license suspended by Health Canada on Sept. 17 after the company was found to be growing cannabis in unlicensed rooms. CannTrust is in a race to get its production back up and running after Health Canada shut down its entire operation in September.